Agile Sciences is developing a therapeutic for treating MDR bacterial infections that enhances current antibiotics using small organic compounds that inhibit bacterial signaling through a novel mechanism of action so bacteria cannot turn on defense mechanisms needed for antibiotic resistance, hence drug resistant infections can be effectively treated with antibiotics.
Primary Application Area: Biotech, Pharma
Technology Development Status: Prototype
FIGURES OF MERIT
Value Proposition: The WHO has declared antibiotic resistance as one of the three greatest threats to human health. In the US, infectious disease is the third-leading cause of death with more than two million cases of multidrug resistance resulting in over 23,000 deaths, $21B in healthcare costs, and $34B in lost productivity costs. This crisis is driven by the rapid acquisition of resistance by MDR pathogens and the lack of introduction of new antibiotics that act via a novel MOA. Currently, antibiotic resistance is generally documented within four years following FDA approval of an antibiotic and in some cases within less than a year. Agile Sciences' has a novel strategy to treating these MDR infections through the use of compounds that prevent bacteria from turning on antibiotic resistance mechanisms. These compounds restore antibiotic susceptibility so that drug resistant bacteria are sensitive to antibiotic treatment. When used as adjuvants, Agile Sciences' compounds have the potential to increase the efficacy of antibiotics against MDR bacterial infections. Furthermore, preliminary analyses have indicated that these compounds have desirable pharmaceutical properties and positive safety profiles making them good candidates for a drug development program.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 11T
GOVT/EXTERNAL FUNDING SOURCES
Vetted Programs/Awards: Featured company for Council for Entrepreneurial Development Life Sciences Innovation Room presenter - 2015 and 2016
SBIR/STTR Awards: $294,309, STTR/NIH/NIAID, 1/1/16-12/31/16
Yr 1 -$641,088, Yr 2 - $596,514, STTR/NIH/NIAID, 07/01/2015-06/30/2017
Yr 1 - $635,323, Yr 2 - $832,651, SBIR/NIH/NIAID, 12/15/2014-11/30/2016
Yr 1 - $672,768, Yr 2 - $826,326, STTR/NIH, 07/15/2014-06/30/2016
$300,000, SBIR/NIH/NIAID, 02/01/2013 - 01/31/2014
$499,586, SBIR/NIH/NIAID, 09/01/2010 – 03/31/2014
$672,768, SBIR/NIH/NIDCR, 09/30/2011 – 08/31/2012...
External Funding to Date: $1.4M seed funding/series A
$250,000 partner milestone payments
$84,480, Bay Area Lyme Foundation, 08/16/2013 - 05/31/2014
$35,000, Bay Area Lyme Foundation, 12/14/2012
$75,000, Cystic Fibrosis Foundation, 02/01/2011 - 01/31/2012